Neurovascular, Muscle, and Skin Changes on [18F]FDG PET/MRI in Complex Regional Pain Syndrome of the Foot: A Prospective Clinical Study.
Complex Regional Pain Syndrome
Muscle
Nerve
Skin
[18F]FDG PET/MRI
Journal
Pain medicine (Malden, Mass.)
ISSN: 1526-4637
Titre abrégé: Pain Med
Pays: England
ID NLM: 100894201
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
received:
25
12
2020
revised:
05
08
2021
accepted:
01
10
2021
pubmed:
1
11
2021
medline:
2
4
2022
entrez:
31
10
2021
Statut:
ppublish
Résumé
The goal of this study is to demonstrate the feasibility of simultaneous [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) for noninvasive visualization of muscular, neurovascular, and skin changes secondary to complex regional pain syndrome (CRPS). Seven adult patients with CRPS of the foot and seven healthy adult controls participated in our [18F]FDG PET/MRI study. All participants received whole-body PET/MRI scans 1 hour after the injection of 370MBq [18F]FDG. Resulting PET/MRI images were reviewed by two radiologists. Metabolic and anatomic abnormalities identified, were grouped into muscular, neurovascular, and skin lesions. The [18F]FDG uptake of each lesion was compared with that of corresponding areas in controls using a Mann-Whitney U-test. On PET images, muscular abnormalities were found in five patients, neurovascular abnormalities in four patients, and skin abnormalities in two patients. However, on MRI images, no muscular abnormalities were detected. Neurovascular abnormalities and skin abnormalities in the affected limb were identified on MRI in one and two patients, respectively. The difference in [18F]FDG uptake between the patients and the controls was significant in muscle (P = .018) and neurovascular bundle (P = .0005). The increased uptake of [18F]FDG in the symptomatic areas likely reflects the increased metabolism due to the inflammatory response causing pain. Therefore, our approach combining metabolic [18F]FDG PET and anatomic MR imaging may offer noninvasive monitoring of the distribution and progression of inflammatory changes associated with CRPS.
Identifiants
pubmed: 34718774
pii: 6414205
doi: 10.1093/pm/pnab315
pmc: PMC8807071
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Banques de données
ClinicalTrials.gov
['NCT03195270']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-346Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.
Références
Pain. 1997 Nov;73(2):123-139
pubmed: 9415498
J Nucl Med. 2016 Feb;57(2):215-20
pubmed: 26493207
Mol Pain. 2018 Jan-Dec;14:1744806918799127
pubmed: 30124090
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Clin J Pain. 2007 Jun;23(5):449-57
pubmed: 17515744
Skeletal Radiol. 1998 May;27(5):262-5
pubmed: 9638836
Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(Suppl 1):4-10
pubmed: 27134625
IEEE Trans Med Imaging. 1994;13(4):601-9
pubmed: 18218538
J Hand Surg Am. 1995 May;20(3):458-63
pubmed: 7642927
Pain. 2001 Oct;94(1):1-6
pubmed: 11576739
Pain. 2010 Aug;150(2):268-274
pubmed: 20493633
J Nucl Med. 2018 Jun;59(6):967-972
pubmed: 29097408
Lancet Neurol. 2003 Nov;2(11):687-97
pubmed: 14572737